NeuroGenomeX

固相生物科學公司收到STTR二期贈款項目的標題為:藥物發現鉛優化芯片的發展。他們獎資助在2009年美國複蘇與再投資法案和他們的項目將解決飼料複合鉛優化芯片的進一步發展和商業化(Multizyme芯片)高通量代鉛化合物的類似物加上細胞篩選生物活性的快速識別衍生品。這種能力直接影響藥物發現的一個關鍵瓶頸;即鉛化合物的高效優化與最優開發藥物藥理性質。固相生物科學公司提出把六個生物催化與生物活性化合物的藥理篩選提供快速識別特異性的目標,這是一個新的範例鉛優化。此外,Multizyme芯片平台將在相關行業,適合領導優化包括農用化學品、化妝品和藥妝品。固相技術將因此提高競爭力和效率的製藥、化妝品、化學工業,將作為豐富的新的和改進的商業產品。這項研究的廣泛影響是固相生物科學的進步將實現向創造更好、更安全的藥物,這些藥物降低開發成本,提高製藥行業的整體效率。固相將生成Multizyme芯片供製藥和生物技術公司,以促進他們的購買鉛優化程序,特別是那些涉及天然product-derived和複雜的合成小分子線索。低溫貯藏技術開發的第二階段將使芯片的銷售和chip-handling設備生產階段,並將允許固相技術平台的無縫滲透進入該公司的目標市場。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

海濱療法是創造新的藥物治療來糾正或改善脆性X綜合征,自閉症和其他障礙的大腦發育。

中樞神經係統是神經生理學bio-marker公司開發和營銷係統,可以客觀地測量精神病藥物對人體的生理影響。

百樂滿製藥公司是一個藥物研發公司專注於病態血管組件包括癌症、眼部疾病(黃斑變性和糖尿病性視網膜病變)、關節炎、纖維化疾病(肺纖維化)子宮內膜異位、骨質疏鬆症和皮膚疾病(牛皮癬和過敏性皮炎)。帕洛瑪擁有知識產權有關的一係列小分子藥物通過一個集成設計平台,定製和行業標準計算工具治療上述疾病的潛在治療。

Optimata有限公司是一個私營企業以科學為基礎的跨學科公司從事biosimulation技術優化藥物治療協議。Optimata與製藥和生物技術公司合作夥伴開發有效的疾病通過模擬疾病新的治療方法流程。這個旨在減少投放市場的時間和開發成本,同時提高競爭力的新開發藥物。

預示腫瘤生物科學是一個公司,專注於評估病人對藥物的臨床試驗。公司使用CIVO技術提供藥物適當濃度的不同地區多個藥物的腫瘤,而腫瘤仍在病人。